Bukwang Pharmaceutical Co., Ltd. (003000.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	215.1B	200.7B	160.1B	125.9B	190.9B
Cost of Revenue	116.4B	105.0B	85.7B	75.9B	111.5B
Gross Profit	98.7B	95.7B	74.3B	50.0B	79.4B
Operating Expenses
R&D Expense	18.0B	25.1B	23.4B	34.6B	24.3B
SG&A Expense	36.3B	24.8B	16.8B	22.1B	19.8B
General & Admin Expense	17.3B	5.5B	4.3B	4.5B	5.1B
Selling & Marketing Expense	2.9B	19.4B	12.5B	17.6B	14.8B
Other Expenses	42.4B	31.7B	32.5B	30.9B	35.6B
Total Operating Expenses	87.1B	81.6B	72.7B	87.5B	79.7B
Cost and Expenses	203.4B	186.6B	158.5B	163.4B	191.1B
Operating Income (EBIT)	11.6B	14.2B	1.6B	(37.5B)	(230.6M)
Non-Operating
Interest Income	6.2B	4.7B	4.4B	3.1B	1.4B
Interest Expense	(1.1B)	3.9B	6.5B	3.8B	1.8B
Net Interest Income	7.3B	815.6M	(2.1B)	(727.8M)	(320.3M)
Other Non-Op Income/Expense	(2.9B)	(7.8B)	(4.6B)	(2.1B)	(802.2M)
Non-Operating Income (excl Interest)	200.00	—	(1.9B)	(1.7B)	—
EBT (Pre-Tax Income)	8.7B	6.4B	(3.0B)	(39.6B)	(1.0B)
Income Tax Expense	(136.7M)	(6.0B)	489.2M	(5.2B)	3.2B
Bottom Line
Net Income	8.9B	12.6B	(2.6B)	(31.3B)	(2.5B)
Earnings from Cont. Ops	8.8B	12.4B	(3.5B)	(34.4B)	(4.2B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	8.9B	12.6B	(2.6B)	(31.3B)	(2.5B)
Per Share
Basic EPS	₩61	₩152	(₩39)	(₩458)	(₩36)
Diluted EPS	₩61	₩152	(₩39)	(₩458)	(₩36)
Revenue Per Share	₩2,202	₩2,034	₩2,339	₩1,841	₩2,789
Shares
Basic Shares Outstanding	97.7M	98.7M	68.5M	68.4M	68.5M
Diluted Shares Outstanding	97.7M	98.7M	68.5M	68.5M	68.5M
Profitability Metrics
EBITDA	16.8B	19.7B	7.6B	(31.5B)	4.9B
D&A	5.1B	5.5B	4.1B	4.3B	5.1B
EBIT	11.6B	14.2B	3.5B	(35.8B)	(230.6M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026